BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ImmunID Appoints Veteran Industry Executive Bernhard Sixt as New CEO


7/24/2013 6:56:47 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ImmunID Appoints Veteran Industry Executive Bernhard Sixt as new CEO

GRENOBLE, France--(BUSINESS WIRE)-- ImmunID, the pioneer in molecular immune diagnostics, today announced the appointment of Dr. Bernhard Sixt as president and chief executive officer. Dr. Sixt is co-founder and former CEO of Agendia, a leading molecular diagnostics company. Dr. Nicolas Pasqual, ImmunID’s co-founder and former chief executive officer, has been appointed chief scientific officer.

Nicolas Pascal, said, “Bernhard Sixt has deep experience in molecular diagnostics. As a co-founder and CEO he built Agendia from a fledgling start-up into an internationally recognized innovator in molecular cancer diagnostics. We are pleased to have attracted him and I warmly welcome Dr. Sixt to help us bring ImmunID to the next level of molecular diagnostics: precision medicine.”

Bernhard Sixt, CEO, said, “ImmunID has succeeded in establishing a reliable platform that yields high quality first-in-class molecular immune diagnostics, and a solid patent portfolio in one of the most exciting emerging fields in the diagnostics space. I look forward to using my experience in further building the company and leading the effort to further establish ImmunID’s leadership together with Nicolas Pasqual and his highly skilled team.”

Dr. Sixt has over 25 years of pharmaceutical industry experience in the development and commercialization of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham (now part of GE Healthcare), and Nycomed (now part of Takeda). He is a co-founder of Agendia and has served as the company’s CEO from 2003 until 2011. Dr. Sixt holds a Master of Science degree in Biochemistry and Chemistry from Ludwig Maximilians University, and a PhD from the Technical University, both in Munich, Germany.

About ImmunID

ImmunID is pioneering the field of molecular immune diagnostics since 2005, offering two commercial products. Its proprietary CE-marked flagship product ImmunTraCkeR evaluates the T cell receptor repertoire diversity at the genomic level. The company is ISO9001 certified and runs an ISO13485 accredited research and production facility in the MINATEC high-tech campus in Grenoble, France, and provides research and testing services worldwide to leading clinical centers and blue-chip pharmaceutical companies such as Roche and Sanofi-Pasteur. http://www.immunid.com

Contact:

Capricorn One

Hans Herklots, +41 79 598 7149

Managing Director

capricorn1@bluewin.ch

or

ImmunID

Bernhard Sixt, +33 438 785 770

President and CEO

bsixt@immunid.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES